Ms. Lu brings a wealth of experience from her distinguished tenure at Sequoia Capital China, where she joined in 2005 and ascended to the position of partner by January 2015. During her nearly 13-year stint with Sequoia, she was instrumental in making direct investments in numerous promising early and mid-stage companies. Her strategic investments, including Jianfan Biology (300529), New Industry Biology (300832), ARMA (ARMA), Robust Medical (300888), Shanghai IRay (688301), and Shenzhen Jingtai, have since matured into leading entities within their respective medical sectors.

In early 2018, capitalizing on her extensive background in medical marketing and project cooperation, Ms. Lu founded Redhill Capital, which she currently leads as an Executive Partner. The firm, under her guidance, focuses on early-stage investments in medical technology and biotech companies. Redhill Capital has a robust portfolio with key investments in industry pioneers such as Breo (688793),Cofoe Medical Technology (301087), and Liangyihui, all of which stand at the frontier of Chinese medical innovation. Ms. Lu's has completed a degree in clinical medicine from Tongji Medical College of Huazhong University of Science and Technology in 1996, an MBA from the Chinese University of Hong Kong in 2004, and an EMBA in Health Management from Changjiang Business School in 2017

Honorary achievements:

2018 、2020-2023 Forbes China's top 25 best female venture capitalist;

Qingke venture 2021s50 Chinese female investors;

Invest in China's best early-stage investor in 2020;

In 2018, 2019 and 2020, it won the top 30 outstanding innovative figures in financing China's equity investment

China's best female investor of the year in financing in 2020;

"Annual medical and health investor" in the 4th Zhuoyue list of medical and health investment in 2020;

2021 "annual medical and health investors" in the 5th Zhuoyue list of medical and health investment;

China master fund alliance 2020 China's top 11 best female direct investment fund investors;

China master fund alliance 2021 China's top 20 best female direct investment fund investors;

Qingke venture 2021s50 Chinese female investors;

Medical group "top ten influential figures in China's venture capital in 2019"

The medical group ranked sixth among the "top 100 most influential people in China's venture capital of medical great health in 2019"

2017 VB100 investor of the year

The star project "Jianfan biology" won the top 10 best exit case in China's medical and health service industry in 2016.